Zepbound

Zepbound causes heartburn primarily through one mechanism: slowed gastric emptying. Tirzepatide delays how quickly food and acid leave the stomach.

UnitedHealthcare processes pharmacy benefits through OptumRx, so Zepbound denials come back as OptumRx adverse determinations.

Introduction Tricare denials for Zepbound® (tirzepatide) follow the same two-level appeal structure as other pharmacy denials, but the clinical arguments that win are specific…

Medicare denials for Zepbound are frustrating because the rules changed in late 2024 and most prescribers and pharmacists haven’t caught up.

Medicaid denials for Zepbound (tirzepatide) follow a predictable pattern, and the appeal follows a predictable counter-pattern.

Introduction Kaiser Permanente’s integrated HMO model means Zepbound® denials come from Kaiser’s internal Drug Coverage and Utilization Management committee, not from an outside PBM….

Humana’s business is heavily Medicare-weighted, which puts Zepbound in a tough spot on Part D plans.

Zepbound does not need a chemical taper. There is no withdrawal syndrome, no receptor downregulation that has to be unwound slowly.

Zepbound (tirzepatide) is available online through telehealth platforms in 2026.